1. ITV Report

Guernsey linked to danger drug

A Guernsey registered company has had its Cambridgeshire based factory closed down after 'serious concerns' about the drugs it produces.

Importation of the drug GcMaf into the island has also been banned from today.

GcMaf is a blood product that claims to treat a range of conditions, including cancer, HIV and autism.

The UK's Medicines and Healthcare Products Regulatory Agency (MHRA) did an unannounced inspection of the production site in Milton, Cambridgeshire today after concerns from the medicines regulator in Guernsey.

A Guernsey company which makes an unlicensed drug has had its factory closed amid fears materials used aren't fit for human consumption.

There are concerns the product may be contaminated and it was decided that the production site doesn't meet Good Manufacturing Practice.

More than 10,000 vials were seized and production of the unlicensed medicine has stopped.

People are now being warned not to buy it it.

These products may pose a significant risk to people’s health. Not only were the manufacturing conditions unacceptable but the originating material was not suitable for human use. GcMAF products labelled as ‘First Immune’ are not licensed medicines and have not been tested for quality, safety or effectiveness. People should not start treatment with these specific products. It is important that patients currently taking these products seek their doctor’s advice as soon as possible. People should continue taking prescribed medicines and follow the advice of their doctor.

– Gerald Heddell, MHRA Director of Inspection, Enforcement and Standards

Locally, Health Authorities are also warning islanders that importing the drug GcMaf is now illegal.

People known to be currently taking the substance are being informed by letter of the importation ban – previously individuals were only able to import it for personal use once they had been informed of our concerns before obtaining a licence.

Please note that there is no current information suggesting the product has caused direct harm to anyone’s health, however anyone concerned about the product, or its ban, is encouraged to talk to their medical advisor for advice and reassurance.

Given the findings of the MHRA inspection and its subsequent warning, Guernsey authorities felt decisive action was needed to implement a complete ban of its importation – under the Import (Control) (Guernsey) Order, 2010.

The MHRA is continuing its investigation in the UK and we will continue to support it.’

– Ed Freestone, Assistant Director Strategic Commissioning and Chief Pharmacist